TY - JOUR
T1 - Treatment of Group A Streptococcal Pharyngitis in Children
T2 - Results of a Prospective, Randomized Study of Four Antimicrobial Agents
AU - Ginsburg, C. M.
AU - McCracken, G. H.
AU - Steinberg, J. B.
AU - Crow, S. D.
AU - Dildy, B. F.
AU - Cope, F.
AU - Zweighaft, T.
PY - 1982/2
Y1 - 1982/2
N2 - Penicillin V, benzathine/procaine penicillin G, cefadroxil monohydrate, and erythromycin estolate were randomly assigned for therapy of group A streptococcal pharyngitis in 198 children. All patients improved within 24 hours of initiating therapy. Reinfection with a new group A streptococcal serotype occurred in 13 patients, 12 developing 7 to 12 days afrer stopping therapy and 11 becoming symptomatic. Relapse with the same organism oc curred in 16 patients, only 5 (31%) of whom were symptomatic. Antibody titer rises, antibiotic resistance of group A organisms, presence of penicillinase- producing staphylococci, and lack of compliance were not related to re current infections. There were no significant differences between the failure rates of the four test drugs: penicillin V, 12%; benzathine/procaine penicillin G, 12%; cefadroxil monohydrate, 5%; and erythromycin, 2%.
AB - Penicillin V, benzathine/procaine penicillin G, cefadroxil monohydrate, and erythromycin estolate were randomly assigned for therapy of group A streptococcal pharyngitis in 198 children. All patients improved within 24 hours of initiating therapy. Reinfection with a new group A streptococcal serotype occurred in 13 patients, 12 developing 7 to 12 days afrer stopping therapy and 11 becoming symptomatic. Relapse with the same organism oc curred in 16 patients, only 5 (31%) of whom were symptomatic. Antibody titer rises, antibiotic resistance of group A organisms, presence of penicillinase- producing staphylococci, and lack of compliance were not related to re current infections. There were no significant differences between the failure rates of the four test drugs: penicillin V, 12%; benzathine/procaine penicillin G, 12%; cefadroxil monohydrate, 5%; and erythromycin, 2%.
UR - http://www.scopus.com/inward/record.url?scp=0020031850&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0020031850&partnerID=8YFLogxK
U2 - 10.1177/000992288202100203
DO - 10.1177/000992288202100203
M3 - Article
C2 - 7035049
AN - SCOPUS:0020031850
SN - 0009-9228
VL - 21
SP - 83
EP - 88
JO - Clinical Pediatrics
JF - Clinical Pediatrics
IS - 2
ER -